ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 Jul 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

12 Jun 2024 19:22:16 By Nasdaq GlobeNewswire

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

29 May 2024 19:21:24 By Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

08 May 2024 07:25:00 By Nasdaq GlobeNewswire

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

30 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

29 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

17 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

10 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

26 Mar 2024 10:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

20 Feb 2024 10:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

06 Feb 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

29 Jan 2024 07:24:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

22 Jan 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

21 Dec 2023 00:30:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

04 Dec 2023 16:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

04 Dec 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

27 Nov 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

16 Nov 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

08 Nov 2023 07:25:00 By Nasdaq GlobeNewswire

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

30 Oct 2023 07:25:00 By Nasdaq GlobeNewswire